微創醫療(00853.HK)附屬引入中金(03908.HK)等投資者 涉資逾1.5億美元
微創醫療(00853.HK)公佈,其目標公司Microport NeuroTech獲六名投資者認購共約203.25萬股新發行A輪優先股,總代價約3,126萬美元;另附屬公司MicroPort Scientific Investment向該等投資者轉讓目標公司約772.04萬股普通股,代價約1.19億美元。完成後,目標公司所轉讓普通股將重新分類及重新指定爲A輪優先股,而目標公司投資後估值將達約17.5億美元。
目標公司於香港、英屬處女羣島及中國設有附屬,其主要從事神經血管疾病(包括出血性卒中、腦動脈粥樣硬化及急性缺血性卒中)的治療及通路類醫療器械的研發、製造及商業化。
該6名投資者包括中金公司(03908.HK)、HHF Group、BVF III(BVI) Holding L.P.、Biolink Healthcare Investment、Star Wave Ventures及Always Enterprises。於該等交易完成及轉換可換股債券後,該6名投資者合共持有目標公司約8.57%股權,至於附屬公司的持股量由69.89%降至54.64%。
公司認爲,是次增資及引入新投資者將爲目標集團帶來進一步加強其產品研發和市場開拓所需的資金,從而有助於目標集團更好地提升其市場競爭力、拓寬市場資源,並促進快速發展,亦有利於進一步提升集團的品牌影響力及市場價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.